Ondine BiomedicalFRA:VF5 31 Buyback Yield % is -18.68 as of Jul. 11, 2026. GuruFocus rates FRA:VF5 with a GF Score™ of 31/100 and a GF Value™ of €0.10 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 742 Biotechnology companies, Ondine Biomedical ranks worse than 66.04% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Ondine Biomedical's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:VF5 vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Ondine Biomedical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ondine Biomedical Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ondine Biomedical's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Ondine Biomedical's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ondine Biomedical (FRA:VF5) has a Buyback Yield % of -18.68 as of Jul. 11, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Ondine Biomedical and its competitors. According to the industry distribution chart, Ondine Biomedical ranks #490 out of 742 companies in the Biotechnology industry, placing it in the top 66%.
Is Ondine Biomedical's Buyback Yield % too high?
Ondine Biomedical's current Buyback Yield % is -18.68. Based on the distribution chart, Ondine Biomedical ranks #490 out of 742 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ondine Biomedical has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ondine Biomedical's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ondine Biomedical ranks #490 out of 742 companies for Buyback Yield %. This places Ondine Biomedical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Ondine Biomedical and its competitors. Ondine Biomedical's current Buyback Yield % is -18.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ondine Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Ondine Biomedical (FRA:VF5) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.10, compared to a current price of €0.15 — trading 50% above its estimated fair value. The current Buyback Yield % is -18.68. Ondine Biomedical's overall GF Score™ is 31/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Ondine Biomedical (FRA:VF5), the current Buyback Yield % is -18.68 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ondine Biomedical (FRA:VF5) Overvalued in 2026?
Based on GuruFocus' analysis, Ondine Biomedical stock appears to be overvalued.
The current stock price of €0.15 is trading 50% above its estimated GF Value™ of €0.10.
GuruFocus considers Ondine Biomedical to be Significantly Overvalued.
Key valuation signals for FRA:VF5:
Buyback Yield %: -18.68
GF Value™: €0.10 vs. price of €0.15 (50% above fair value)
No single metric tells the full story. See the FRA:VF5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ondine Biomedical Inc is a life sciences company, focusing on the development of photodisinfection-based therapies to provide solutions to drug-resistant infections. The company has created a platform technology called antimicrobial photodynamic disinfection, or photodisinfection, to help prevent and help treat infections across different therapeutic areas in healthcare and industry settings. Canada is the major revenue generator for the group. The company has one reportable operating segment that is antimicrobial photodynamic therapy (aPDT) products.
31GF Score
Get the complete analysis for FRA:VF5
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VF5 has been successfully added to your 
